You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Noninvasive Platform to Assess Maternal Risk for Perinatal Complications in the First Trimester

    SBC: Cradle Genomics, Inc.            Topic: NICHD

    Limited information is available about early human placentation when many pregnancy pathologies originateTo address this knowledge gap and begin development of robust diagnostic tool to manage pregnancy complicationswe propose a pilot study based on a highly sensitive immune assay and our company s base technologyTrophoblast Retrieval and Isolation from the CervixTRICTRIC uses a Pap smearconsidere ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. A therapeutic approach for potential prevention of aromatase inhibitor-induced bone loss

    SBC: NANOMEDIC INC            Topic: NIA

    AbstractIn this SBIR Phase I applicationour goal is to demonstrate proof of concept of our lead chelating agent as a potential therapeutic for the prevention of osteoporosis induced by aromatase inhibitorAItherapy in postmenopausal women with hormone receptor positive breast cancerAlthough AI therapy shows great improvements in cancer free and overall survivalits treated patients face a risk of os ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Daily and localized NSAID sonophoresis for symptomatic treatment of knee osteoarthritis

    SBC: Zetroz Systems LLC            Topic: NIA

    Project SummaryOsteoarthritisOAis the most common type of arthritisaffecting overmillion adults in the United States inand represents overof medical office visits according to the Centers for Disease Control and Prevention and the National Institutes of HealthOverof individuals overhave symptomatic OA and reduced mobility due to the diseaseOA pain is often mitigated with conservative treatment app ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction

    SBC: Recursion Pharmaceuticals, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Chronic diseases of aging account for a significant proportion of healthcare spending and result in a painful and limiting existence for many tens of millions of Americans and hundreds of millions of people around the world. Recursion Pharmaceuticals has developed a drug discovery platform that re-purposes known drugs for the treatment of such diseases. The pla ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Establishing the POROS Intracellular Delivery System as a Platform for Cellular Therapeutics

    SBC: OPENCELL TECHNOLOGIES, INC.            Topic: 100

    Abstract SignificanceIntracellular delivery of nucleic acids to immune cells is an important component of many current and anticipated cellular therapiesincluding chimeric antigen receptor T CellCAR Ttherapies for the treatment of cancerThese therapies use immune cells called T cellseither from the patient themselvesor a healthy donorand genetically engineer them to kill the tumor cellsThe genetic ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Single-cell Phosphoprotein Assay to Evaluate Brain Tumor Therapeutic Resistance

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    Although signal transduction inhibitors occasionally offer clinical benefit for cancer patientssignal flux emanating from oncogenes is often distributed through multiple pathwayspotentially underlying the resistance which causes failure of most such inhibitorsMeasuring signal flux through multiple pathwaysin response to signal transduction inhibitorsmay help uncover network interactions that contr ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Use of Stem Cells to Enhance and Extend Continuous Glucose Monitoring in Vivo

    SBC: Cell And Molecular Tissue Engineering LLC            Topic: 200

    Implantable glucose sensor based monitoring of blood glucose levels in diabetic patients has been available for overyearsHoweverdespite improvements to sensor functionalityrecalibration of the sensor device is often a necessity in order to compensate for unreliable sensor performanceThe development of highly accurate and long lived implantable sensors is critical to the development of theartificia ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Demonstrating the feasibility of CCG-257081 as a preventive therapy to inhibit bleomycin-induced lung fibrosis in mice

    SBC: FIBROSIX INC.            Topic: 102

    ABSTRACT Front-line therapy for patients diagnosed with Hodgkin’s lymphoma or germ cell cancers includes the drug bleomycin, a highly effective agent with a debilitating side effect. About 10-12% of bleomycin-treated patients develop pneumonitis with progression to pulmonary fibrosis during therapy as a direct result of bleomycin. An estimated 10-20% of these cases are fatal. The current standar ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of an a MC1R selective companion diagnostic imaging probe

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    The melanocortinreceptorMC Ris over expressed on uveal and cutaneous melanoma cellsbut notin healthy normal tissuesWe have developed a proprietary ligandMTIthat binds to MC R inmelanoma cells with high affinity and specificityThrough our SBIR Phase I contractwedemonstrated that MC R targetedAc DOTA MTIlacks of overt toxicity at single doses thatproduce significant efficacy against uveal and cutane ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients

    SBC: Thetis Pharmaceuticals LLC            Topic: 300

    ABSTRACTThetis plans to investigate TPan innovative and potential first in class therapeutic agentas an oral therapy for the induction and maintenance of remission of intestinal inflammation symptoms in ulcerative colitisUCpatientsWhile the precise etiology of UC is unknownit is thought to result from an inappropriate inflammatory response to commensal gut bacteria in genetically susceptible indiv ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government